Biological E has place in India's COVID-19 vaccine market following Corbevax' approval
The Drugs Controller General of India (DCGI) recently approved Biological E’s Corbevax vaccine as the first heterogeneous COVID-19 booster vaccine in India for adults above 18 years who have received two shots of Covaxin or Covishield. Corbevax has the added advantage of scalability and thermostability, making it suitable for deployment in low-resource settings, says GlobalData.
The data and analytics company notes that Biological E has now carved out its place in the COVID-19 vaccine market due to its capacity to produce over a 100 million monthly doses.
In April 2022, DCGI approved Corbevax for children aged 5-12 years after already being used to vaccinate children aged 12-14 years. The current COVID-19 vaccine market in India is dominated by the Serum Institute of India and AstraZeneca’s (LSE: AZN) Covishield and Bharat Biotech’s Covaxin. Covishield accounts for nearly 78% of all vaccine dosages administered. So far, Indians were vaccinated only with homologous shots.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze